✦ LIBER ✦

Second line treatment of antiangiogenic therapy with celecoxib and weekly paclitaxel for advanced non-small cell lung cancer (NSCLC)

✍ Scribed by Stani, Simonetta Chiara; Sarmiento, Roberta; Mansueto, Giovanni; Bonginelli, Paola; Comella, Giovanni; Ferrau, Francesco; Magnani, Elena; Carillio, Guido; Sciacca, Venerina; Gasparini, Giampietro

Book ID: 118572053
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 189 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92321-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiangiogenic agents as second-line the

Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer

✍ Karen L. Reckamp 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 370 KB

794 Weekly paclitaxel (W-PAC) as second-

794 Weekly paclitaxel (W-PAC) as second-line therapy in cisplatin pretreated patients with advanced non-small cell lung cancer (NSCLC)

✍ G.L. Ceresoli; V. Gregorc; S. Cordio; K. Bencardino; A. Spreafico; C. Cozzarini; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Second-line chemotherapy with weekly pac

Second-line chemotherapy with weekly paclitaxel in patients with advanced non-small-cell lung cancer

✍ Luis Ángel León Mateos; Juan Fernando Cueva Bañuelos; María Teresa Curiel García 📂 Article 📅 2002 🏛 Springer Milan 🌐 Spanish ⚖ 49 KB

Weekly docetaxel as first-line therapy f

Weekly docetaxel as first-line therapy for elderly patients with advanced non-small cell lung cancer (NSCLC)

✍ Hainsworth, J.D; Burris, H.A; Morrissey, L.H; Litchy, S; Greco, F.A 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Phase II study of weekly paclitaxel as s

Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer

✍ Ceresoli, Giovanni Luca; Gregorc, Vanesa; Cordio, Stefano; Bencardino, Katia Bru 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Second-line (SL) weekly paclitaxel (P) i

Second-line (SL) weekly paclitaxel (P) in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing first-line (FL) carboplatin/paclitaxel (C/P)

✍ Socinski, M.A; Kies, M; Unger, P; Peterman, A; Gillenwater, H.H; Schell, M; Bakr 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 231 KB